AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04355468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Free Anaesthesia
Description: Before the induction of general anesthesia, a single-shot thoracic paravertebral block (ThPVB) was performed at the Th3-Th4 level. An insulated needle was used, connected to a peripheral nerve stimulator. 0.5% bupivacaine (0.3 ml∙kg-1) was then injected after a negative aspiration test. The efficacy of the blockade was checked after 20 min on both sides of the thorax with a plastic ampoule of saline. A difference in the sensation of cold between the sides of the thorax was assumed to indicate an effective block. Afterwards a continuous intravenous infusion of lidocaine and ketamine was started:~1. immediately after anesthesia induction, lidocaine was administered as an i.v. bolus at a dose of 1.5 mg∙kg-1 and ketamine in an i.v. bolus of 0.35 mg∙kg-1;~2. followed by an infusion of lidocaine 2.0 mg∙kg-1∙h-1 for 2 hours, continued at a dose of 1.2 mg∙kg-1∙h-1, and ketamine infusion 0.2 mg∙kg-1∙h-1 for 2 hours, continued at a dose of 0.12 mg∙kg-1∙h-1.
Study NCT03783793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training App
Description: Mindfulness training in the study was performed using a new app called Wildflowers. With this app participants were able to choose and complete a variety of guided meditations over the 3 week training period. Wildflowers includes guided meditations such as breathing, body scans, and open monitoring practices and also provides didactic content in the form of lessons and information about the benefits of mindfulness training.
Study NCT03783793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training With 2048
Description: The training app for the control condition was based on an open source code for a popular cognitive training app called 2048 that is marketed as a fun and relaxing puzzle game. Within 2048, participants slide numbered tiles around a grid, matching tiles of the same value. Instead of tiles disappearing, as in Candy Crush or other similar grid-sliding games, matching 2 numbered tiles in 2048 combines them into 1 new tile displaying the sum of the previous 2 numbers. For example, two 2-tiles linked side-by-side become a 4-tile, whereas 2 matched 4-tiles become an 8-tile, and so on. The goal is to match tiles until the sum of 2048 is reached on a single tile. There is no time limit.
Study NCT03216577 — intervention group
Intervention type: OTHER
Intervention: Phone interview measuring health-related quality of life variables
Description: A phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.
Study NCT03243487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: structured adherence management program
Description: Structured adherence management service (PAMS) program and a web-based information program designed for participants beginning positive airway pressure therapy
Study NCT03243487 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard care provided at a VA Sleep Center for participants beginning positive airway pressure therapy
Study NCT00420238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept (Enbrel)
Description: 50 mg injection once weekly
Study NCT03524001 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compare VVi mode versus DDD bifocal stimulation through crossover randomization
Description: All patients undergo bifocal right ventricular resynchronization therapy: right atrial lead is implanted, whereas first ventricular lead is placed in His bundle area, and the second ventricular lead in the right ventricle apex.Then the leads are connected to CRT-D generator.After the implant, all devices are programmed in VVI mode. After the first 40±10 days (first f-up) patients are 1:1 randomized to VVI mode 40 beats/minute (placebo arm) or bifocal DDD-mode 60 beats/minute.After six months (second follow-up) a clinical and instrumental assessment equal to baseline is performed. Then arms cross-over is performed (from VVI-mode to bifocal DDD-mode and vice versa). At 12 months (end of follow-up) an evaluation equal to that performed at 6 months is assessed. Echocardiographic data are unravelled to the investigator that plans stimulation mode able to determine the best clinical improved.
Study NCT03524001 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Compare VVi mode versus DDD bifocal stimulation through crossover randomization
Description: All patients undergo bifocal right ventricular resynchronization therapy: right atrial lead is implanted, whereas first ventricular lead is placed in His bundle area, and the second ventricular lead in the right ventricle apex.Then the leads are connected to CRT-D generator.After the implant, all devices are programmed in VVI mode. After the first 40±10 days (first f-up) patients are 1:1 randomized to VVI mode 40 beats/minute (placebo arm) or bifocal DDD-mode 60 beats/minute.After six months (second follow-up) a clinical and instrumental assessment equal to baseline is performed. Then arms cross-over is performed (from VVI-mode to bifocal DDD-mode and vice versa). At 12 months (end of follow-up) an evaluation equal to that performed at 6 months is assessed. Echocardiographic data are unravelled to the investigator that plans stimulation mode able to determine the best clinical improved.
Study NCT01588275 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mandibular repositioning appliance (MRA) (SomnoDent)
Description: bibloc MRA type SomnoDent starting at 70% protrusion of the mandibula
Study NCT00420238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04587557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling with social contextual information
Description: Four out of 100 stories from a storytelling app (SAHK, 2013) that incorporated social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
Study NCT04587557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Storytelling without social contextual information
Description: Four out of 100 stories from a storytelling app (SAHK, 2013) without social contextual information, and inter-personal skills were selected. The intervention was in small group format, consisted of eight sessions across four weeks, two sessions per week, 30 minutes per session.
Study NCT04587557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Children with ASD
Description: Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with ASD.
Study NCT02879487 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar needle electrode
Description: Colpotomy during total laparoscopic hysterectomy
Study NCT02252341 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: N-Acetyl-Cysteine
Description: drug: N-Acetyl-cysteine N-Acetyl-cysteine 1800 mg a day for 12 weeks versus placebo for 12 weeks
Study NCT03558568 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation is an established surgical method for Parkinson's Disease.
Study NCT03234140 — intervention group
Intervention type: GENETIC
Intervention: Genome Wide Association Studies
Description: Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data.
Study NCT03234140 — intervention group
Intervention type: GENETIC
Intervention: Single-nucleotide polymorphisms's genotyping
Description: Analyze of the influence of single-nucleotide polymorphisms on circulating t(14;18) levels
Study NCT02081248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consent Form Specific Format 1
Description: The Consent Form Specific Format 1 is the 'Standard Consent'. The standard consent does not have the format of two-columns with changes in layout readability, organization of content, typography and use of plain language. Standard consents are already used by sites for the BMT CTN 0901, 1101, 1203, and 1301 clinical trials.
Study NCT02081248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consent Form Specific Format 2
Description: The Consent Form Specific Format 2 is the 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent is two-columns with changes in layout readability, organization of content, typography and use of plain language.
Study NCT04564300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Both groups will perform a standardized training protocol
Study NCT04564300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Training
Description: Both groups will perform a standardized training protocol
Study NCT03160313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: InFuSE
Description: Each session includes a 45-minute education and group discussion. A 60-minute exercise component then completes the session. Each topic was specifically picked and tailored to benefit Veterans with TBI. The education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities. The activities are included to help improve understanding and promote group discussion. The exercise piece consists of a warm-up, endurance training (20-30 minutes), strengthening (15 minutes), balance/cognitive training (15 minutes), and a cool-down.
Study NCT03160313 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education/Group Discussion
Description: Each week you will participate in a 1 hour health education class with other Veterans. Each topic was specifically picked and tailored for Veterans with TBI. These education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities which are included to help improve understanding and promote group discussion.
Study NCT03460509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugammadex
Description: Dose-response
Study NCT03460509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Dose-response
Study NCT04822805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Patients with recurrent high-grade gliomas are being enrolled , treated with anlotinib 12mg once daily for 14 days every 3 weeks until disease progression or unacceptable toxicity.The dose can be adjusted to 10mg or 8mg according to the specific conditions of the patient.
Study NCT04320030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-DPA-714 PET/CT scan
Description: Pretherapeutic \[18F\]-DPA-714 PET/CT scan
Study NCT01255748 — intervention group
Intervention type: RADIATION
Intervention: Proton Therapy, Photon Therapy, SRS, Brachytherapy
Description: Outcomes Tracking
Study NCT03250364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multilayer bandage
Description: See arm/group descriptions
Study NCT03250364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double compression bandage
Description: See arm/group descriptions
Study NCT03250364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohesive bandage
Description: See arm/group descriptions
Study NCT03250364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhesive compression bandage
Description: See arm/group descriptions
Study NCT04587557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Children with ASD
Description: Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with ASD.
Study NCT04587557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Children with TD
Description: Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with TD.
Study NCT04587557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Children with TD
Description: Four out of 100 stories from a storytelling app (SAHK, 2013) were selected for children with TD.
Study NCT03011294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Description: Standard treatment for sleep apnea
Study NCT03011294 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal strip
Description: Placebo
Study NCT01474551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: All patients would be treated with vemurafenib given orally at 960 mg twice a day, which was the phase III dose. One cycle is 4 weeks long.
Study NCT03250364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping bandage
Description: See arm/group descriptions
Study NCT03250364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD) + Intermittent Pneumatic Compression
Description: MLD using a modification of the strokes described by Leduc will be applied to lymphedema resorption. It will be included resorption maneuver in the oedematous areas of the affected limb, in cranial to caudal direction, since the physiotherapist seeing a change in the tissue qualities of the oedema. Then, the subjects will be received thirty minutes of Intermittent Pneumatic Compression (EureducTM) with a pression of 40 mmHg.
Study NCT02539290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detection of ovulation
Description: Detecting the luteinizing hormone surge using test sticks in a urine sample
Study NCT02539290 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Detection of ovulation
Description: Detecting the luteinizing hormone surge using test sticks in a urine sample
Study NCT02539290 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine flushing
Description: Injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge
Study NCT02539290 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Vaginal flushing
Description: Injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge
Study NCT02539290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual intercourse
Description: Sexual intercourse on the day of the intervention and the following day
Study NCT02539290 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sexual intercourse
Description: Sexual intercourse on the day of the intervention and the following day
Study NCT03250364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb exercises
Description: After the bandage will be put, proprioceptive neuromuscular facilitation exercises without resistance in two diagonal in asymmetrical reciprocal patterns with the affected limb will be taught. The first diagonal into flexion from hitch hike to swat fly, and into extension from swat fly to hitch hike, and the second diagonal from hand in opposite pocket to carry tray, and into extension from carry tray to hand in opposite pocket. These exercises must be done at home two times per day, ten repetitions each exercise.
Study NCT03250364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational strategy
Description: Instructions about lymphatic system anatomy and pato-physiology, the prevention and identification of possible lymphedema complication or infection, how to use and exercise this arm, avoidance of trauma, injury, an excess of heat and arm constriction.
Study NCT00129311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline
Description: 5 mg capsules taken by mouth. Participants take 5 mg once a day for the first week of the study, then increase the dose to 5 mg twice a day for 6 weeks, then take 5 mg once a day during the last week of the study. Participants receiving the placebo pill take 1 pill per day for the first week of the study and 1 pill twice a day for the other weeks.
Study NCT00129311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01666847 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Milking the umbilical cord before cord clamping
Description: The procedure will involve positioning the neonate below the level of the placenta and milking approximately 20cm of umbilical cord three times over 10-20 seconds total from the placental end to the neonate. The cord will then be clamped and the neonate handed to the awaiting medical team for routine care of a premature infant.
Study NCT02491229 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hepafast
Description: Two weeks of Hepafast three times a day and additionally 200 kcal followed by 10 weeks of Hepafast two times a day and a meal according to LOGI diet
Study NCT02704247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CARDIOSPACE System
Description: * autonomic nervous system test~* tilt test~* ultrasound exploration at rest (heart / vessels)~* laser doppler + iontophoresis test~* sub-maximal exercise test
Study NCT02432547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept is a soluble decoy receptor and is produced by fusing all-human DNA sequences of the second immunoglobulin (Ig) domain of human VEGF receptor (VEGFR) 1 to the third Ig domain of human VEGFR-2, which are then fused to the Fc region of human IgG-1. By binding to VEGF-A, aflibercept prevents activation of the native VEGF receptors, VEGFR-1 and VEGFR-2. The study sites will be supplied by Bayer with aflibercept. Intravitreal injection of 2mg in 0.05 ml aflibercept will be administered to the study eye, according to a pre-defined treat and extend regimen.
Study NCT02432547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Aflibercept is a soluble decoy receptor and is produced by fusing all-human DNA sequences of the second immunoglobulin (Ig) domain of human VEGF receptor (VEGFR) 1 to the third Ig domain of human VEGFR-2, which are then fused to the Fc region of human IgG-1. By binding to VEGF-A, aflibercept prevents activation of the native VEGF receptors, VEGFR-1 and VEGFR-2. The study sites will be supplied by Bayer with aflibercept. Intravitreal injection of 2mg in 0.05 ml aflibercept will be administered to the study eye, according to a pre-defined treat and extend regimen.
Study NCT02432547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted laser therapy
Description: In the experimental group, targeted laser photocoagulation will be applied to areas of peripheral retinal ischaemia 1 month after the initial intravitreal aflibercept. The trial design allows another session of targeted laser photocoagulation 1 month later to complete the treatment if required. Wide-field photography is planned at 3 months to determine if further targeted laser photocoagulation is required, and if so a third session can be applied. The laser settings are based on those used in current clinical practice and have been prospectively defined in the protocol.
Study NCT01762709 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The VT 4 ml/kg group
Description: the dependent lung will be ventilated with a TV of 4 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
Study NCT01762709 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The VT 6 ml/kg group
Description: the dependent lung will be ventilated with a TV of 6 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
Study NCT00934076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva plus AT-101
Description: 150 mg of Tarceva taken once daily in a continuous regimen expressed in 3 week cycles.~Oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis.
Study NCT04629560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miracle Fruit
Description: one miracle fruit tablet of 100 mg 10-15 minutes before lunch and dinner versus supportive measures. Patients assigned to receive the miracle fruit will receive written instructions regarding the use of the fruit. Patients should put the fruit tablet or powder in the mouth and gently chew/suck to dissolve and cover the tongue with the powder
Study NCT02601573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.
Study NCT02601573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.
Study NCT02491229 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: LOGI diet
Description: For twelve weeks, this group eats meals according to the Low Glycemic and Insulinemic Diet (LOGI).
Study NCT00540618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-507
Description: Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
Study NCT00540618 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00540618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-507
Description: Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)